摘要
抗体偶联药物(antibody-drug conjugate,ADC)是新型的分子靶向药物,由大分子单克隆抗体与小分子细胞毒药物偶联而成,通过单克隆抗体与肿瘤细胞表面表达分子的特异性结合,将细胞毒药物定向运输至肿瘤细胞中,既提高了化疗的安全性,又保证了治疗的精确性,成为多种实体瘤和淋巴瘤的研究热点.ADC研究的热门靶点包括CD30、人表皮生长因子受体2、肿瘤相关钙信号转导蛋白2等,目前在血液肿瘤,如淋巴瘤,及实体瘤,如乳腺癌、胃癌和尿路上皮癌等肿瘤中有相对成熟的研究证据,在肺癌中也显示出初步疗效,是肿瘤精准治疗时代最具潜力的治疗策略之一.综述旨在汇总截至2022年11月ADC在实体瘤治疗中的研究进展,并展望ADC的发展前景.
Antibody-drug conjugate(ADC)is a novel targeted agent that consists of monoclonal antibody(mAb)and cytotoxic drug,delivering drugs to tumor cells by reaching target antigens expressed on cancer cells,minimizing toxicity to normal tissue and ensuring the efficacy of drugs.ADC has become a hot spot in multiple solid tumors and in lymphoma.Targets in ADC researches include CD30,human epidermal growth factor receptor 2,tumor-associated calcium signal transducer 2,and so on.Data has been relatively mature in haematological malignancies,such as lymphoma,and in solid tumors such as breast cancer,gastric cancer,and urothelial carcinoma studies,and has also been promising in lung cancer studies.To date,ADC is one of the most couraging treatment strategy in the era of precision therapy.This review aims to summarize the progress in ADC researches in solid tumors by November,2022,and to provide the perspectives in the futureof ADC studies.
作者
翟怡心
许子宜
谢同济
邢镨元
Zhai Yixin;Xu Ziyi;Xie Tongji;Xing Puyuan(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Bejing 100021,China)
出处
《中国肿瘤临床与康复》
2023年第2期92-98,共7页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
北京肿瘤防治研究会(2022-038-ZZ)。
关键词
实体瘤
抗体偶联药物
靶点
Solid tumor
Antibody-drug conjugate
Target
